It is demonstrated that AM-derived exosomes represent a promising therapeutic approach for TBI by suppressing pyroptosis and facilitating functional recovery through inhibition of the SERPINE1/HIF-1α/NLRP3 axis.
Abstract
Objective
Pyroptosis is recognized as a critical contributor to the secondary injury following traumatic brain injury (TBI), and its inhibition has been shown to preserve neuronal integrity and improve neurological outcomes. This study aimed to investigate the therapeutic effects of Astragalus membranaceus (AM)-derived exosomes on TBI-induced pyroptosis and elucidate the underlying mechanism.
Methods
AM-derived exosomes were purified via sucrose density gradient ultracentrifugation and subsequently characterized. The effects of AM-derived exosomes in TBI were assessed in HT22 neuronal cells subjected to scratch injury and in a controlled cortical impact (CCI) mouse model of TBI. Neurological outcomes were evaluated through histopathological staining, neurologic severity scoring, grip strength testing and neurological function evaluation. Pyroptosis was detected using flow cytometry following caspase-1 and propidium iodide staining. NLRP3 activator BMS-986299 was used to determine whether activation of NLRP3 could reverse the inhibitory effects of AM-derived exosomes on pyroptosis.
Results
AM-derived exosomes significantly enhanced cell viability and reduced neuronal pyroptosis and pyroptotic markers (cleaved caspase-1, GSDMD-N, IL-1β and IL-18), alongside downregulating SERPINE1, HIF-1α, and NLRP3 expression. Activation of NLRP3 by BMS-986299 partially abolished the anti-pyroptotic effects mediated by AM-derived exosomes. In vivo, systemic administration of AM-derived exosomes ameliorated neurological deficits, improved motor function, attenuated hippocampal neuronal loss, and suppressed SERPINE1/HIF-1α/NLRP3 signaling. AM-derived exosomes showed excellent biocompatibility and the ability to penetrate the blood-brain barrier.
Conclusion
These findings demonstrate that AM-derived exosomes represent a promising therapeutic approach for TBI by suppressing pyroptosis and facilitating functional recovery through inhibition of the SERPINE1/HIF-1α/NLRP3 axis.
PQQ attenuates secondary injury after TBI in male mice, in association with increased markers of PINK1/Parkin‐mediated mitophagy initiation and suppressed ASS1/CPS1‐driven arginine biosynthesis, identifying a candidate dual‐axis mechanism and nominating the mitophagy‐arginine axis as a target for neuroprotection in TBI...
Ya-Nan He, Lu-Fei Yu, Yi-Xun Lu et al.· CNS Neuroscience & Therapeut...· 0 citations
Experimental evidence for the preclinical application of Ginkgolide B in TBI intervention is provided, revealing that GB significantly mitigated acute neurological deficits, improved subacute motor coordination, and rescued chronic cognitive impairment and anxiety-like behaviors in TBI mice.
Yian Xiao, Kai Luo, Min Peng et al.· Journal of Neuroimmunology· 0 citations
BACKGROUND
Microglial ferroptosis is a key risk factor promoting neuroinflammation after ischemic brain injury (IBI). Although Compound 21 (C21) has neuroprotective and anti-inflammatory properties, its role in modulating microglial ferroptosis in IBI remains unexplored.
METHODS
IBI was induced in C57BL/6 mice via tr...
Yi-Jiu Wu, Xin-Qiang Zhou, Xu-Fang Huo et al.· Experimental Neurology· 0 citations
Background: Radiation-induced brain injury (RIBI) is a common side effect of cranial radiotherapy that severely impairs patients’ neurological function and quality of life. Currently, effective and safe remedies for RIBI remain limited. Paeoniflorin (PF), a key component of total glucosides of paeony (TGP) extracted fr...
Zhong-Fang Zhao, Xiao-Ju Chen, Xiao-Han He et al.· ACS Omega· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.